Repligen Corporation (NASDAQ:RGEN) Receives $165.00 Average Price Target from Analysts

Shares of Repligen Corporation (NASDAQ:RGEN) have been given an average rating of “Moderate Buy” by the eighteen research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, thirteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $165.00.

Several analysts recently commented on RGEN shares. Canaccord Genuity Group cut their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research report on Tuesday, July 7th. Barclays boosted their price target on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Finally, HC Wainwright raised their target price on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a report on Monday, March 23rd.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC purchased a new position in Repligen during the 3rd quarter valued at $29,000. Bayforest Capital Ltd bought a new position in Repligen during the 4th quarter worth about $32,000. Rachor Investment Advisory Services LLC purchased a new position in Repligen during the fourth quarter valued at approximately $33,000. Los Angeles Capital Management LLC bought a new position in shares of Repligen in the 4th quarter worth $36,000. Finally, Farther Finance Advisors LLC raised its holdings in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $147.25 on Thursday. The firm has a market cap of $8.31 billion, a P/E ratio of 163.61, a PEG ratio of 2.84 and a beta of 1.06. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $100.99 and a twelve month high of $175.77. The company has a 50 day moving average of $128.69 and a 200 day moving average of $133.52.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The company had revenue of $194.25 million for the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.Repligen’s revenue was up 14.8% compared to the same quarter last year. During the same period last year, the firm posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts expect that Repligen will post 1.99 EPS for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.